ZyVersa Therapeutics

ZyVersa Therapeutics ZyVersa is committed to developing biopharmaceuticals that address unmet medical needs of patients with inflammatory and renal diseases.

ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging two licensed proprietary product platforms to develop pharmaceutical products that address unmet medical needs in the areas of renal and inflammatory diseases. Lead renal candidate, Phase 2a-ready VAR 200, mediates removal of excess intracellular lipids in the kidney’s filtration system that contribute to kid

ney damage leading to end-stage kidney disease. Lead anti-inflammatory drug candidate, inflammasome ASC inhibitor (IC 100), blocks initiation and perpetuation of damaging inflammation that’s pathogenic in a multitude of inflammatory diseases.

Address

2200 N. Commerce Parkway, Suite 208
Weston, FL
33326

Telephone

+17542311688

Website

Alerts

Be the first to know and let us send you an email when ZyVersa Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category